Big Pharma Lied About Bundling All Data in One Release
That's why I know that this stock is being manipulated. Although it may sound like wishful thinking, this is still a buy. A total failure in Bap results will probably force the Company to sell itself for its Tysabri franchise and residual R & D, IP, etc. The real question is whether to wait for the next set of results and buy on the drop/or spike. I've been trading around the position and selling calls. I expect the implieds to drop, but not that significantly, so this could still be an income play (r at least pull in a little downside protection from call premiums). I think Big Pharma separated the press releases for a reason. The head of Neurologic Drugs at the FDA knows alot about this drug and hinted that if there was a subset of patients benefitting from Bap, there would be a path for approval.
imo; this sell-off below $12 is legit for the news. OK; now what? What's next to be announced? We know the 1st study was expected to be a dud. We got a dud. The stock is down ~15%. In 6 + hrs, maybe down more/maybe less. But now what? Below $12/shr....is it a 'sell'? My argument all along it won'y go to $9 or $10. But we'll just have to see what all these option pos's do.